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Abstract: Lung cancer is the second most commonly occurring non-cutaneous cancer in the United States with the highest mortality 
rate among both men and women. In this study, we utilized three lung cancer microarray datasets generated by previous researchers 
to identify differentially expressed genes, altered signaling pathways, and assess the involvement of Hedgehog (Hh) pathway. The 
three datasets contain the expression levels of tens of thousands genes in normal lung tissues and squamous cell lung carcinoma. The 
datasets were combined and analyzed. The dysregulated genes and altered signaling pathways were identified using statistical methods. 
We then performed Fisher’s exact test on the significance of the association of Hh pathway downstream genes and squamous cell lung 
carcinoma.
395 genes were found commonly differentially expressed in squamous cell lung carcinoma. The genes encoding fibrous structural 
  protein keratins and cell cycle dependent genes encoding cyclin-dependent kinases were significantly up-regulated while the ones 
encoding LIM domains were down. Over 100 signaling pathways were implicated in squamous cell lung carcinoma, including cell 
cycle regulation pathway, p53 tumor-suppressor pathway, IL-8 signaling, Wnt-β-catenin pathway, mTOR signaling and EGF signaling. 
In addition, 37 out of 223 downstream molecules of Hh pathway were altered. The P-value from the Fisher’s exact test indicates that Hh 
signaling is implicated in squamous cell lung carcinoma.
Numerous genes were altered and multiple pathways were dysfunctional in squamous cell lung carcinoma. Many of the altered 
genes have been implicated in different types of carcinoma while some are organ-specific. Hh signaling is implicated in squamous cell 
lung cancer, opening the door for exploring new cancer therapeutic treatment using GLI antagonist GANT 61.
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Introduction
Cancer is the third leading cause of death   worldwide, 
and lung cancer is the second most commonly occurring 
non-cutaneous cancer with the highest mortality rate 
among all cancers. There are 1.38 million new cases 
of lung cancer every year, along with 1.23 million 
deaths due to lung cancer.1 Based on the histological 
types of the cells, lung cancer is categorized into two 
major types, small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). SCLC occurs almost 
exclusively in heavy smokers, and makes up about 
14% of all lung cancers. NSCLC is a general term 
for several different types of lung cancer, including 
squamous  cell  carcinoma,  in  which  the  malignant 
cells appear larger in size in comparison to SCLC. 
Collectively,  NSCLC  subtypes  contribute  to  about 
86% of all lung cancers.2 The average survival time 
for patients with SCLC is about 10 months. The sur-
vival time for patients with NSCLC varies depending 
on the stage of the disease. Patients with an advanced 
stage of NSCLC also have an average survival time 
of 10 months.3 The 5-year survival rate for SCLC is 
only 6%, and for NSCLC, the rate is merely 16%, 
making the average rate 14%, one of the lowest rates 
of all cancers.3,4
Similar to that of many other cancers, the molec-
ular basis of lung cancer is genetic mutation. When 
mutation  occurs,  the  expression  levels  of  related 
genes and their products are altered. Genes in a cell 
interact with each other in pathways that regulate cell 
growth, division, DNA repair, and apoptosis.5,6 Unduly 
expressed or under expressed genes dysregulate bio-
chemical pathways including metabolic pathways and 
signaling pathways. Lung cancer is a very complex 
and heterogeneous disease. To develop better cancer 
treatments,  one  needs  to  understand  the  molecular 
mechanisms  of  carcinogenesis,  cancer  progression 
and  metastasis  and  to  understand  how  the  cancer 
related genes interact in networks and pathways. The 
development of microarray technology has made it 
possible to describe the cellular and molecular states 
of cells quantitatively and to study the expression lev-
els of many genes simultaneously.7–10   Microarray gene 
expression profiling of cancer   tissues and other disease 
tissues has been performed by many researchers.8–16 
Several  groups  of  researchers    conducted  gene 
expression study exploring mRNA gene expression 
  differences in normal cells and   different types of lung 
cancer  cells  including  several  non-small  cell  lung 
cancer cells.14–16
In this study, we utilized three squamous cell lung 
cancer microarray datasets14–16 generated by   previous 
researchers to identify dysregulated genes and their 
associated  signaling  pathways  and  to  assess  the 
involvement of hedgehog pathway in squamous cell 
lung cancer.
Materials and Methods
This  research  utilizes  three  microarray  datasets 
  generated by previous researches for NSCLC. The 
first dataset was generated by a group of researchers 
to identify a list of genes that can be used to classify 
different types of lung cancer.14 The dataset includes 
the  microarray  gene  expression  profiles  of  127 
adenocarcinoma specimens, 21 squamous cell lung 
carcinomas, and 20 pulmonary cardinoids, as well 
as  17  normal  cell  samples.  Affymetrix  HG-U95A 
oligonucleotide probe microarray chips were used in 
the experiment. Each chip represents about 12,625 
human gene probes.
The second dataset was created by another group 
of  researchers  who  worked  more  specifically  with 
squamous cell lung carcinomas. Their work paired 
normal lung tissue and squamous cell lung cancer tis-
sue from 5 patients, and analyzed their results to find 
which genes were expressed differently in squamous 
cell cancer compared to normal cells.15 The relations 
and interactions between the altered genes were also 
investigated.  Affymetrix  HG-U133A  chips  were 
used. Each chip represents 14,500 well-characterized 
probes.
The third dataset was produced by a group aimed at 
identifying highly dysregulated genes with biological 
significance in tumor progression.16 The dataset has 
46  tumor  samples,  including  13  adenocarcinomas 
and 32 squamous cell lung carcinomas, and 45 paired 
nontumor control samples. In the study, gene expression 
levels were investigated as a function of tumor type, 
stage and differentiation grade. Affymetrix HG-U133A 
chips were used. Each chip represents 54,675 mRNA 
probes.
The focus of this study was on squamous cell lung 
cancer. We used only the relevant subsets from the 
three datasets. The raw data (cel files) were provided 
for  the  first  dataset,  and Affymetrix’s  MicroArray 
Suite 5 (MAS5) implemented in GeneSpring software Signaling pathways in lung carcinoma
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version 11.0 (Silicon Genetics, Redwood City, CA) was 
used to normalize the expression levels of genes for the 
dataset. The 75 percentile shift was conducted for the 
second dataset. The median of each sample was trans-
formed to the median of all samples for both datasets. 
We then carried out statistical analysis to identify the 
differentially expressed genes between squamous cell 
lung cancer cells and normal cells. The gene expres-
sion levels were log-transformed. For the first data-
set, two sample Welch t-test17 was deployed to test 
the null hypothesis that the mean expression level 
of a gene from cancer cells is the same as the mean 
expression level of the gene from normal cells. For 
the second dataset, paired t-test was used. In all tests, 
we assumed that samples were independently selected 
random samples from the two populations: squamous 
cell lung carcinomas tissue and normal lung tissue 
and  the  population  distributions  are  approximately 
normal; this is equivalent to assume that most of the 
time the fluctuation of gene expression levels within 
cancer tissues or within normal lung tissues is not 
that far from the average levels and the fluctuation is 
symmetric to the average levels.14–16 Multiple testing 
corrections based on Benjamini and Hochberg false 
discovery rate (FDR) were conducted.18,19 The two-
tailed P-value 0.05 was used as the cutoff for signifi-
cance to obtain a set of genes that were significantly 
altered in squamous cell lung carcinomas. For the 
third dataset, the list of differentially expressed genes 
provided in the supplementary table to the original 
paper was used. They were identified using FDR cor-
rection. We then found the intersection of the three 
sets to obtain the genes that are commonly dysregu-
lated in all three datasets.
The set of commonly altered genes was analyzed 
using the software IPA (Ingenuity® Systems, http://
www.ingenuity.com). Related molecular functions and 
canonical  pathways  were  identified. Top  functional 
groups were identified using Fisher’s exact test20 with 
P-value 0.05 as the cutoff for significance and marked 
with the ratio of the number of dysregulated genes that 
are belong to the functional group to the total number 
of genes in IPA knowledge database that are annotated 
to  the  group.  Significance  of  association  between 
the  differentially  expressed  genes  and  the  canoni-
cal  pathways  recorded  in  IPA  knowledge  database 
was evaluated with the same measures, P-value from 
Fisher’s exact test and the concentration ratio.
In addition, we examined the expression levels of 
genes that are associated with hedgehog (Hh) signal-
ing pathway. Hh signaling plays important roles in a 
variety of normal cellular processes including embryo-
genesis, patterning of organ structures, tissue repair, 
cellular  proliferation  and  survival.21,22 The  analysis 
of the connection between the altered genes with Hh 
pathway was performed using IPA and   Fisher’s exact 
test. P-value 0.05 was used as the cutoff.
Results and Discussion
Differentially  expressed  genes  and  their  biological 
functions—Sorting all the P-values for the genes, we 
can determine which genes have the highest difference 
in  expression  levels  in  the  samples,  and  therefore 
are  most  likely  to  have  a  difference in  expression 
levels in the population. A commonly used P-value 
cutoff of 5% with FDR correction was used. There 
are 1951 genes that were significantly down regu-
lated in the first dataset, 532 in the second dataset and 
1685 genes in third dataset while 1909, 474, 1404 
are up regulated respectively in the first, second and 
third datasets. 395 differentially expressed genes are 
common to all the three dataset, including 148 up-
regulated and 247 down-regulated. These genes are 
presented in Supplemental Tables 1 and 2. The top 
30 up/down regulated genes are shown in Tables 1 
and 2 and the fold change of their expression levels 
are also presented in Figure 1. Since the experiments 
conducted for the three datasets were carried out in 
different  settings  using  different  microarray  chips, 
in order to compare the fold change of each gene 
across different experiments, fold change values were 
normalized for each dataset.
The biological functions associated with the 395 
commonly dysregulated genes were obtained using 
IPA, as they are most likely to be connected to the 
mechanism  of  cancer  growth.  The  results  show 
that the genes are associated with many molecular 
and cellular functions as well as different types of 
diseases including cancer and genetic disorder. The 
top  molecular  and  cellular  functions  are  presented 
in Table 3.
Canonical  signaling  pathways  associated  with 
differentially  expressed  genes—To  examine  dys-
functional signaling pathways, we utilized all altered 
genes (without FDR correction) that are common to 
all three datasets. FDR correction was not conducted Shi et al
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for identifying genes since the focus was on individual 
pathways.
There are 1122 differentially expressed genes with 
506 commonly up-regulated and 616 down-regulated. 
The  core  analysis  using  IPA  suggests  that  over 
100 canonical signaling pathways are implicated in 
squamous cell lung cancer (Supplemental Table 3). 
The top altered pathways include cell cycle: G2/M 
DNA damage checkpoint regulation, RAR activation, 
Wnt/β-catenin  signaling,  mTOR  signaling,  HIF1α 
signaling, as well as EGF signaling. The top 40 sig-
naling  pathways  implicated  in  squamous  cell  lung 
carcinoma are shown in Figure 2.
Downstream  molecules  of  hedgehog  signaling 
pathway—The  hedgehog  signaling  pathway  has 
been  implicated  in  the  development  of  different 
human cancers including prostate cancer, colon can-
cer and basal-cell carcinoma. GLI proteins are the 
effectors of hedgehog signaling. GLI1 and GLI2 are 
the two key members of GLI family and together 
they  have  223  downstream  target  molecules  col-
lected in the IPA knowledge database. We analyzed 
the GLI   target   molecules for their connection with 
squamous  cell  lung  cancer.  Interestingly,  37  out 
of 223 are significantly altered. The 37 associated 
genes are presented in Table 4. 21 of the 37 were 
up-  regulated. 15 of them were considerably differ-
entially expressed in squamous cell lung cancer cells 
with FDR corrected P-values less than 0.05 in all 
three datasets (Supplemental Tables 1 and 2). Eight 
of  them,  CDC45,  CDK1,  CSTA,  HDAC1,  JAG1, 
JUP, KRT15, KRT17, were up-regulated; 7 of the 
genes,  CXCL2,  FHL1,  FOXA2,  PAPSS2,  RHOB, 
SAP18, SYNE1, were down.
The Fisher’s exact test on the 37 genes yields a 
P-value of 0.0484 (,0.05) which indicates the strong 
Table 1. Top up-regulated genes (common to all datasets).
symbol Fold change entrez gene name
D1 D2 D3
KrT6A 11.39 7.47 11.46 Keratin 6A
DST 5.54 5.32 5.07 Dystonin
SerPINB5 4.44 4.54 5.61 Serpin peptidase inhibitor, clade B, member 5
CLCA2 2.08 5.54 4.66 Chloride channel accessory 2
KrT17 1.91 4.55 5.82 Keratin 17
KrT15 3.56 4.84 2.64 Keratin 15
KrT16 3.20 5.08 2.51 Keratin 16
TP63 3.20 4.42 2.69 Tumor protein p63
TFAP2A 6.47 2.48 2.24 Transcription factor AP-2 alpha
AKr1B10 2.95 5.06 2.40 Aldo-keto reductase family 1, member B10
TrIM29 2.24 3.15 4.43 Tripartite motif containing 29
DSP 3.27 3.78 1.89 Desmoplakin
PKP1 1.87 4.03 2.25 Plakophilin 1
CDC20 2.41 2.94 1.92 Cell division cycle 20 homolog
gINS1 2.72 2.43 1.88 gINS complex subunit 1
UBe2C 3.05 2.13 1.86 Ubiquitin-conjugating enzyme e2C
COL17A1 2.71 2.17 1.94 Collagen, type XVII, alpha 1
CCNB1 2.00 2.88 1.86 Cyclin B1
FSCN1 1.85 2.82 1.96 Fascin homolog 1, actin-bundling protein
TPX2 2.14 2.52 1.87 TPX2, microtubule-associated
TOP2A 2.29 2.36 1.87 Topoisomerase (DNA) II alpha
IgFBP2 2.15 2.44 1.85 Insulin-like growth factor binding protein 2
AKr1C1/2 2.01 2.48 1.91 Aldo-keto reductase family 1, member C2
SOX15 2.01 2.34 1.86 SrY-box 15
SFN 1.86 2.47 1.89 Stratifin
CDK1 2.02 2.31 1.83 Cyclin-dependent kinase 1
CSTA 1.89 2.35 1.80 Cystatin A (stefin A)
CCNB2 2.17 1.98 1.85 Cyclin B2
UCK2 1.84 2.30 1.81 Uridine-cytidine kinase 2
SLC16A1 1.82 2.16 1.95 Solute carrier family 16, member 1Signaling pathways in lung carcinoma
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association  of  hedgehog  signaling  with  non-small 
cell lung cancer. The contingency table for GLI1 and 
GLI2 downstream molecules is given in Table 5.
Genes in a cell interact with each other through a 
sequence of orchestrated events in pathways. Aberrant 
cell signaling along the pathways breaks the organized 
events,  promotes  proliferation,  inhibits  apoptosis, 
induces  angiogenesis,  and  facilitates  the  cancer  to 
spread. Our study combined three microarray datasets 
to  explore  more  stable  biomarkers  or  drug  targets 
for  squamous  cell  lung  cancer  and  the  pathways 
  implicated. The results indicate that the expression 
levels of many genes were altered and multiple path-
ways were dysfunctional in squamous cell lung carci-
noma (Supplemental Tables 1 and 2, Fig. 1).
The  altered  genes  encode  cytokines,  enzymes, 
growth factors, kinases, transporters transmembrane/
nuclear receptors and transcription regulators. They 
participate in variety of molecular activities in differ-
ent biological processes. The molecules were located 
in multiple cellular locations in extracellular space, 
cytoplasm, nucleus, and plasma membrane.
As we can see from Table 1, the top up-  regulated 
genes  include  members  of  the  keratin  family, 
keratin 6A, keratin 15, keratin 16, and keratin 17. 
Their expression levels were significantly elevated. 
Keratins are intermediate filament–forming proteins 
that provide mechanical support and perform a diver-
sity of other functions in epithelial cells.23–25 All four 
of them are epithelial keratin genes. They are asso-
ciated  with  molecular  functions  such  as  structural 
constituent of cytoskeleton and protein binding and 
participate in cytoskeleton organization, cell differ-
entiation, regulation of cell proliferation, epidermis 
Table 2. Top down-regulated genes (common to all datasets).
symbol Fold change entrez gene name
D1 D2 D3
CLDN18 -7.48 -4.19 -10.41 Claudin 18
ADh1B -5.40 -7.29 -5.51 Alcohol dehydrogenase 1B, β polypeptide
Ager -6.95 -5.17 -4.07 Advanced glycosylation end product-specific receptor
SFTPC -5.09 -3.29 -8.35 Surfactant protein C
FABP4 -7.37 -5.13 -2.35 Fatty acid binding protein 4, adipocyte
TNNC1 -3.58 -5.02 -3.03 Troponin C type 1
CLIC5 -3.23 -5.27 -3.20 Chloride intracellular channel 5
LIMCh1 -2.81 -5.23 -3.18 LIM and calponin homology domains 1
FOLr1 -4.02 -2.40 -4.25 Folate receptor 1
PgC -3.07 -2.64 -4.78 Progastricsin
CLeC3B -3.07 -3.85 -3.21 C-type lectin domain family 3, member B
TCF21 -4.74 -3.91 -1.93 Transcription factor 21
FCN3 -3.90 -3.78 -2.33 Ficolin (collagen/fibrinogen domain containing) 3
hPgD -3.24 -4.53 -2.15 hydroxyprostaglandin dehydrogenase 15-(NAD)
ABCA8 -3.59 -4.19 -1.97 ATP-binding cassette, sub-family A, member 8
NKX2-1 -4.12 -2.28 -3.14 NK2 homeobox 1
PTPrB -6.15 -2.17 -2.15 Protein tyrosine phosphatase, receptor type, B
CYP2B6 -2.43 -2.41 -4.75 Cytochrome P450, family 2, subfamily B, polypeptide 6
ZBTB16 -4.21 -2.69 -2.22 Zinc finger and BTB domain containing 16
FhL1 -3.29 -3.88 -1.96 Four and a half LIM domains 1
LMO3 -3.41 -1.87 -3.62 LIM domain only 3
gPM6A -2.83 -2.95 -2.73 glycoprotein M6 A
ChrDL1 -3.08 -3.45 -2.05 Chordin-like 1
CACNA2D2 -2.12 -2.88 -3.55 Calcium channel, voltage-dependent, alpha 2/delta subunit 2
TeK -3.49 -3.18 -1.88 TeK tyrosine kinase, endothelial
hSD17B6 -3.10 -2.97 -2.16 hydroxysteroid (17-β) dehydrogenase 6 homolog
FIgF -2.41 -3.53 -2.34 c-fos induced growth factor
LPL -2.20 -2.78 -3.11 Lipoprotein lipase
gPr116 -2.49 -3.13 -2.44 g protein-coupled receptor 116
VIPr1 -3.42 -2.32 -2.35 Vasoactive intestinal peptide receptor 1Shi et al
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development,  intermediate  filament  cytoskeleton 
organization and ectoderm development.
The proteins encoded by keratin 6A are type II cytok-
eratins  (neutral-basic).  These  cytokeratins  organize 
in  pairs  of  heterotypic  keratin  chains,  which  are 
co-expressed  during  differentiation  of  simple  and 
stratified epithelial tissues. Keratin 15, 16 and 17 are 
acidic.   Keratin 16 and 17 are paired with keratin 6 
while keratin 15 is paired with keratin 5 in squamous 
epithelial cells. It has been reported that keratins can 
be used as diagnostic markers in human carcinomas.25 
A recent review on keratin summarized the evidence 
for active keratin involvement in cancer cell invasion 
and metastasis, as well as in treatment   responsiveness.25 
However,  their  involvement  in  squamous  cell  lung 
carcinoma requires further investigation.
Also  significantly  over-expressed  was  cyclin-
  dependent kinase 1 (CDK1). The protein encoded by 
this CDK1 is a member of the Ser/Thr protein kinase 
family. It is a catalytic subunit of the highly conserved 
protein kinase complex known as M-phase promoting 
factor, which is essential for G1/S and G2/M phase 
transitions of eukaryotic cell cycle. The kinase activ-
ity of this protein is controlled by cyclin accumulation 
and destruction through the cell cycle. The phospho-
rylation of this protein also plays important regulatory 
roles in cell cycle control.26–28 CDK1 is involved in 
many signaling pathways including apoptosis signal-
ing; ATM signaling; cell cycle: G2/M DNA damage 
checkpoint regulation; cyclins and cell cycle regula-
tion; role of CHK proteins in cell cycle checkpoint 
control; and sonic hedgehog signaling. In addition, 
several other cell-division cycle proteins including 
CDC20 and CDC45 were up-regulated.
The  top  down  regulated  genes  are  presented 
in  Table  2.  Several  LIM  domain  proteins,  FHL1, 
LIMCH, and LMO3, are in this group. Also included 
is LDB2 (Supplemental Table 2). The LIM domain 
is  a  double-zinc  finger  motif  found  in  a  diversity 
of proteins. The zinc fingers have highly conserved 
cysteines and joined by a 2-amino acid spacer. LIM 
proteins include transcription factors and cytoskel-
etal  proteins.  It  is  reported  that  the  primary  role 
of  LIM  domains  is  in  protein-protein  interaction, 
through the formation of dimers with identical or dif-
ferent LIM domains or by binding distinct proteins. 
  LIM-only proteins are implicated in the control of 
cell proliferation.29,30
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Figure 1. heatmap showing fold change patterns of most altered genes.
Table  3.  Top  molecular  and  cellular  functions  that  are 
associated with commonly dysregulated genes.
category P-value
Cell death (1.97e-17, 1.89e-03)
Cellular growth and proliferation (1.13e-13, 1.29e-03)
Cell cycle (4.01e-13, 1.79e-03)
Cellular movement (2.88e-10, 1.93e-03)
Cellular development (3.86e-10, 1.88e-03)
Cell-to-cell signaling and  
interaction
(1.01e-07, 8.62e-04)
Lipid metabolism (3.46e-07, 1.73e-03)
Small molecule biochemistry (3.46e-07, 1.73e-03)
Dna replication,  
recombination, and repair
(5.31e-06, 1.52e-03)
gene expression (6.49e-06, 1.79e-03)
Cellular assembly and  
organization
(7.95e-06, 1.15e-03)
Molecular transport (3.89e-05, 1.73e-03)
Carbohydrate metabolism (1.09e-04, 8.62e-04)
Protein synthesis (1.36e-04, 5.80e-04)
Cell morphology (1.50e-04, 1.57e-03)
Cellular function and  
maintenance
(3.83e-04, 1.80e-03)
Cellular compromise (4.92e-04, 4.92e-04)
Drug metabolism (4.92e-04, 4.92e-04)
Cell signaling (5.80e-04, 1.14e-03)
Post-translational modification (5.80e-04, 5.80e-04)
Antigen presentation (8.27e-04, 8.62e-04)Signaling pathways in lung carcinoma
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Cell cycle: G2/M DNA damage checkpoint regulation
PAR activation
Mismatch repair in eukaryotes
Factors promoting cardiogenesis in vertebrates
Mitotic roles of polo-like kinase
Cell cycle control of chromosomal replication
p53 signaling
Angiopoietin signaling
IL-8 signaling
Cyclins and cell cycle regulation
IL-3 signaling
Axonal guidance signaling
Growth hormone signaling
Prolactin signaling
Role of CHK proteins in cell cycle checkpoint control
Thrombopoietin signaling
Oncostatin M signaling
ERK5 signaling
Acute phase response signaling
Renin-angiotensin signaling
LPS/IL-1 mediated inhibition of RXR function
Phospholipase C signaling
Erythropoietin signaling
JAK family kinases in IL-6-type cytokine signaling
RAN signaling
Wnt/β-catenin signaling
IL-9 signaling
p70S6K signaling
mTOR signaling
HIF1α signaling
Virus entry via endobytic pathways
Aryl hydrocarbon receptor signaling
G beta gamma signaling
Thrombin signaling
Intrinsic prothrombin activation pathway
TR/RXR activation
EGF signaling
Ephrin receptor signaling
JAK/Stat signaling
Cholecystokinin/Gastrin-mediated signaling
NF-kB signaling
0 1 2 3 4 5 6 7
Figure 2. Altered signaling pathways linked with squamous cell lung carcinoma. The blue bars stand for –log(P-values) that were calculated based on 
the Fisher’s exact test while the red bars represent the ratios of altered genes to the total number of genes involved in the pathways. (The red bars were 
scaled by a factor of 10 so that both P-values and ratios can be contrasted and presented on the same figure.).
FHL1 that encodes a member of the four-and-a-
half-LIM-only  protein  family  was  significantly 
down  regulated.  Expression  of  these  family  mem-
bers occurs in a cell and tissue specific mode and the 
proteins are involved in many cellular processes. The 
reduced expression of FHL1 in lung cancer has been 
recently reported. It was suggested that the inhibitory 
effects  of  FHL1  on  lung  cancer  cell  growth  were 
associated with both the G1 and the G2/M cell cycle 
arrest associated with a marked inhibition of cyclin 
A, cyclin B1 and cyclin D as well as the induction 
of  the  cyclin  dependent  kinase  inhibitors  p21  and 
p27.30   Conversely, several members of cyclin family 
(cyclin A2, cyclin B1, cyclin B2 and cyclin dependent Shi et al
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kinase  I)  were  found  up-regulated  in  lung  cancer 
in  this  study  (Supplemental  Table  1)  while  cyclin 
dependent kinase inhibitors CDKN1A and CDKN1B 
were consistently down-regulated in all three datasets 
(although the down-regulation levels were not above 
the statistical significant threshold).
Down-regulated RHOB is a member of the RHO 
GTP-binding protein family. The RHO family plays 
a crucial role in the dynamic regulation of the actin 
cytoskeleton. Studies suggested that the proteins of the 
family also have a diversity of functions in membrane 
pathways.  The  RHOB  was  shown  to  localize  to 
vesicles of the endocytic compartment, suggesting a 
potential function in regulation of endocytic traffic. 
The expression of active RHOB causes a delay in 
the intracellular trafficking of the epidermal growth 
factor (EGF) receptor through regulating PRK1.31–33
The signaling pathway investigation in this study 
reveals  that  many  of  the  cancer  related  pathways 
reported  in  the  literatures  are  also  responsible  for 
squamous  cell  lung  carcinoma.  They  include  cell 
cycle regulation pathway (P = 1.8E-7), p53 tumor-
suppressor  pathway  (P  =  4.2E-5),  IL-8  signaling 
(P = 1.9E-4), Wnt-β-catenin pathway (P = 0.0038), 
Table 4. gLI1/gLI2 downstream genes commonly differentially expressed in all three datasets.
symbol entrez gene name Type
CSTA↑ Cystatin A (stefin A) Other
DIO2↑ Deiodinase, iodothyronine, type II enzyme
FhL1 Four and a half LIM domains 1 Other
gMFg glia maturation factor, gamma growth factor
INSIg1 Insulin induced gene 1 Other
KrT15↑ Keratin 15 Other
KrT17↑ Keratin 17 Other
PAPSS2 3’-phosphoadenosine 5′-phosphosulfate synthase 2 enzyme
rhOB ras homolog gene family, B enzyme
SPrr2A↑ Small proline-rich protein 2A Other
COL1A1↑ Collagen, type I, alpha 1 Other
CXCL2 Chemokine ligand 2 Cytokine
JAg1↑ Jagged 1 growth factor
MMP9↑ Matrix metallopeptidase 9 Peptidase
MMP11↑ Matrix metallopeptidase 11 Peptidase
PI3↑ Peptidase inhibitor 3, skin-derived Other
PThLh↑ Parathyroid hormone-like hormone Other
SPP1↑ Secreted phosphoprotein 1 Cytokine
TIMP3 TIMP metallopeptidase inhibitor 3 Other
BNC1↑ Basonuclin 1 Transcription regulator
CDC45↑ Cell division cycle 45 homolog Other
CDK1↑ Cyclin-dependent kinase 1 Kinase
FOXA2 Forkhead box A2 Transcription regulator
FOXM1↑ Forkhead box M1 Transcription regulator
gATA6 gATA binding protein 6 Transcription regulator
hDAC1↑ histone deacetylase 1 Transcription regulator
hDAC2↑ histone deacetylase 2 Transcription regulator
hOXA5 homeobox A5 Transcription regulator
ID2 Inhibitor of DNA binding 2 Transcription regulator
KLF4 Kruppel-like factor 4 (gut) Transcription regulator
MeF2C Myocyte enhancer factor 2C Transcription regulator
SAP18 Sin3 A-associated protein, 18 kDa Transcription regulator
SOX2↑ SrY-box 2 Transcription regulator
SYNe1 Spectrin repeat containing, nuclear envelope 1 Other
TSC22D1 TSC22 domain family, member 1 Transcription regulator
JUP↑ Junction plakoglobin Other
PPAP2C↑ Phosphatidic acid phosphatase 2C Phosphatase
note: ↑Up-regulated genes.Signaling pathways in lung carcinoma
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mTOR signaling (P = 0.0042), and EGF signaling 
(P = 0.010) (Fig. 2).
Cell cycle: G2/M DNA damage checkpoint regu-
lation pathway is on the top of the altered pathways. 
G2/M  checkpoint  is  the  second  checkpoint  within 
the cell cycle. It prevents cells from entering mitosis 
when DNA is damaged, providing an opportunity for 
repair and stopping the proliferation of damaged cells 
and helping to maintain genomic stability.26 14 out 
of 49 molecules on the pathway were significantly 
altered in lung cancer including the cyclin-dependent 
kinase 1 (CDK1) which is essential to drive cells into 
mitosis (Supplemental Tables 1 and 2).
p53 activation is induced by a number of stress 
signals, including DNA damage, oxidative stress and 
activated oncogenes. The p53 protein is employed 
as a transcriptional activator of p53-regulated genes. 
This results in cell cycle arrest, cellular senescence 
or apoptosis. 17 out of 49 molecules on the pathway 
were  significantly  altered,  including  up-regulated 
SERPINB5  and  TP63.  Serpin  peptidase  inhibitor, 
clade B (ovalbumin), member 5 (SERPINB5), also 
known as maspin, is a tumor suppressor gene. It was 
reported to block the growth, invasion, and metastatic 
properties of mammary tumors. Its expression was 
down-  regulated in breast tumors, prostate cancer and 
uterine cervix cancer.34–36 It was reported that SER-
PINB5 over-expression increased the rate of apoptosis 
of both preneoplastic and carcinomatous mammary 
epithelial cells and reduced tumor growth through a 
combination of reduced angiogenesis and increased 
  apoptosis.32 However, the role of   SERPINB5 in the 
inhibition  of  tumor  growth  is  rather  complex.  In 
contrast  to  its  reduced  expression  levels  in  breast 
cancer  and  other  types  of  cancer,  SERPINB5’s 
over-expression  in  pancreatic  carcinoma  was  also 
reported.37 A  recent  study  shows  how  it  works  in 
regulating  cell  growth  when  tightly  coupled  with 
the thrombin receptor protease activated receptor-1 
(PAR-1).38  Our  study  indicates  that  SERPINB5 
is  significantly  over-expressed  in  squamous  cell 
lung carcinoma in all three datasets (Table 1). The 
tumor  protein  TP63  is  another  up-regulated  gene 
(Table 1) that encodes a member of the p53 family 
of transcription factors. It acts as a sequence specific 
DNA binding transcriptional activator or repressor. 
Its over-expression has already been documented in 
lung carcinoma.39
EGFR  encodes  a  receptor  for  members  of  the 
epidermal growth factor family. Binding of the protein 
to a ligand induces receptor dimerization and tyrosine 
autophosphorylation  and  leads  to  inappropriate 
activation of the anti-apoptotic Ras signaling cascade, 
eventually leading to uncontrolled cell proliferation. 
Both EGFR and the signal transducer and activator 
STAT1 were up-regulated in the three datasets (based 
on the P-values without FDR correction). EGF recep-
tor signaling has long been studied in searching for 
the treatment of lung cancer40,41 and EGFR inhibitors 
against lung cancer have been explored.42–45 In princi-
ple, it should be feasible to regulate the activity of sig-
naling pathways with noncytotoxic agents. Gefitinib 
and Erlotinib are two agents used in the treatment of 
non-small cell lung carcinoma. These drugs are epi-
dermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor, which interrupt signaling through EGFR in 
target cells.44,45 They improve response rate and sur-
vival, especially in the subpopulation of patients who 
carry  certain  mutations  in  EGFR  gene.  However, 
clinical trials show that EGFR tyrosine kinase inhibi-
tors , like many other drugs, have not been successful 
in curing cancer.44–48
Another important cancer related pathway is Wnt/
β-catenin signaling pathway. Wnt signaling pathway 
is a network of proteins best known for their roles in 
embryogenesis and cancer, but also involved in normal 
physiological  processes  in  adult  animals.46,47  Wnt 
proteins are secreted morphogens that are required 
for basic developmental processes, such as cell-fate 
specification,  progenitor-cell  proliferation  and  the 
control of asymmetric cell division, in many differ-
ent species and organs.49,50 Wnt ligand binds to its 
receptor and stabilizes cytoplasmic β-catenin through 
inhibition  of  the  β-catenin  degradation  complex. 
Table  5.  Contingency  table  for  gLI1/gLI2  downstream 
molecules.
GLI1/2  
downstream
not GLI1/2  
downstream
Differentially  
expressed
37 1085 1122
Not differentially  
expressed
186 7573 7759
223 8658 8881*
note: *8881 is the total number of genes presented on the Affymetrix 
chips that have biological annotations in IPA.Shi et al
282  Cancer Informatics 2011:10
β-catenin is then free to enter the nucleus and activate 
Wnt-regulated genes through its interaction with TCF 
family transcription factors and associated recruitment 
of coactivators. 20 out of 174 Wnt signaling related 
genes are altered in the datasets. Although conflict-
ing roles of Wnt-5 A in cancer have been reported,51 
our data shows it is significantly up-regulated and the 
Wnt inhibitor WIF1 is down-regulated. The P-values 
without FDR correction are consistently below the 
threshold in all three datasets.
mTOR pathway has been extensively explored in 
some other cancers, including renal cell carcinoma, 
and  large  clinical  trials  have  reported  promising 
progression-free  survival  advantage  with  mTOR 
inhibitor drugs in this disease. Our report suggests 
that mTOR signaling may be involved in squamous 
cell lung carcinoma as well, and exploring this path-
way in more depth in squamous cell carcinoma of the 
lung may be needed.52,53
Many hurdles remain in the race to find a better 
treatment to cancer. Recently a cellular screen for 
antagonists of GLI-mediated transcription revealed 
that a small molecule GANT61 was able to selec-
tively inhibit the GLI-mediated gene transactivation, 
which is the last step of the Hh pathway.54 Hh signal-
ing is tightly coupled with Wnt signaling.47 It plays 
important roles in a variety of normal cellular pro-
cesses including embryogenesis, patterning of organ 
structures,  tissue  repair,  cellular  proliferation  and 
survival.21,22 The signaling pathway is activated when 
hedgehog signaling ligands, such as sonic hedgehog, 
bind to the membrane receptor patched (PTCH), and 
thus stop the suppression of the signaling molecule 
smoothened  (SMO)  caused  by  PTCH.  SMO  then 
activates  the  cytoplasmic  protein  SUFU,  which 
releases the GLI family of transcription factors, GLI1 
and  GLI2.  Once  the  GLI  molecules  are  released, 
they translocate to the nucleus, where they bind to 
target genes to start transcription.21,22 The signaling 
process is shown in Figure 3. Hh signaling pathway 
is an important regulator of the embryonic devel-
opment  and  becomes  reactivated  in  cancer.  It  has 
been activated in several human cancers including 
prostate cancer, colon, and small cell lung cancer 
although the pathway seems to be inactive in most 
normal adult tissues.55–58 The inhibition of this path-
way could offer a selective way of controlling just 
the tumor cells. In our data, GLI2 was up-regulated 
although  the  significantly  altered  expression  level 
of GLI1 was not observed. On the other hand, our 
investigation into the group of GLI1 and GLI2 down-
stream molecules using IPA revealed that significant 
number of genes was altered in the group (Table 5). 
The P-value 0.0484 from the   Fisher’s exact test is 
below the commonly used threshold 0.05; indicating 
Hh signaling pathway is involved in squamous cell 
lung carcinoma.
conclusion
By combining three microarray datasets, we created 
a more comprehensive and complete gene expression 
analysis of squamous cell lung cancer. The list of 
altered genes is more reliable than the ones obtained 
from a single setting of experiments, therefore provid-
ing a more dependable set of lung   cancer biomarkers/
drug targets. Equally the group of implicated signal-
ing pathways is more trustworthy. The results of the 
analysis indicate numerous genes were altered and 
multiple pathways were dysfunctional in squamous 
cell lung carcinoma. As discussed above, many of 
the altered genes have been implicated in different 
types  of  carcinoma  although  some  of  the  altered 
genes are organ-specific. Hh signaling is implicated 
in squamous cell lung cancer, opening the door for 
exploring  new  cancer  therapeutic  treatment  using 
GLI antagonist GANT 61. While active in many dif-
ferent types of cancer, Hh pathway is believed to be 
mostly inactive in normal adult tissues, making it a 
good target for cancer treatments. Consequently, the 
treatment based on GANT 61 is likely to cause few 
side effects.
Inactive
PTCH PTCH SMO
Hedgehog ligand Active
SMO
SUFU SUFU
GLI, PTCH, ...
GLI
GLI
Target gene Target gene
GLI
Cytoplasm
Nucleus
Membrane
Figure 3. Mechanism of hedgehog signaling.Signaling pathways in lung carcinoma
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